All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, What is the rationale behind step-up dosing of glofitamab in patients with mantle cell lymphoma (MCL)?
What is the rationale behind step-up dosing of glofitamab in patients with MCL?
He begins by outlining the challenges faced in relapsed/refractory (R/R) MCL, the study aims and design. Phillips notes the promising efficacy of the treatment with high overall and complete response rates. He highlights that further research would investigate the long-term durability of this treatment, and discusses adverse events.
Follicular lymphoma: A summary of the hot topics presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Follicular lymphoma (FL), a form of non-Hodgkin lymphoma, is an indolent but incurable lymphoproliferative disorder of...
Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL
During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox